Cocaine Use Disorder Market Outlook to Strengthen During the Forecast Period (2026-2036) with Emerging Therapies and Rising Healthcare Needs | DelveInsight

The cocaine use disorder market across the U.S., EU4, U.K. and Japan was approximately $55 million in 2025, with about 2.48 million diagnosed prevalent cases; both are forecast to grow through 2036. No medication has FDA approval specifically for CUD, and treatment relies primarily on off-label therapies. Investigational candidates include STALICLA’s mavoglurant, Embera’s EMB-001 and Tempero Bio’s TMP-301, but development stages vary and future launches or approvals are not assured.

Analysis

The investment signal is much weaker than the pipeline narrative suggests. A market forecast built on diagnosed prevalence is not equivalent to a commercially reachable market: treatment uptake, durable adherence, payer coverage, and evidence of benefit over behavioral care will determine whether any candidate creates meaningful revenue. The article provides no forecast endpoint, pricing, treated-patient assumptions, or independently verifiable evidence for OMS527, so it does not support a revenue or valuation revision for Omeros (OMER).

For OMER, this is best treated as optionality, not a near-term fundamental catalyst. The key company-specific unknown is OMS527’s development status and next value-inflecting event; without that, headline-driven enthusiasm could outrun evidence. Across the field, multiple mechanisms and competing candidates raise the bar for differentiation. In particular, another mGluR5 candidate could compete for trial attention and eventual adoption if efficacy is not clearly differentiated. Even positive clinical results would need to translate into practical prescribing and reimbursement before the market forecast becomes investable.

Over days, any OMER reaction to the report may be sentiment-led. Over 1–3 months, verify whether Omeros discloses a defined OMS527 trial plan, enrollment, or data timing. Over 6–18 months, the thesis depends on controlled efficacy and safety data, followed by regulatory and access progress. The contrarian read is that large unmet need and prevalence do not guarantee a large drug market: stigma, diagnosis gaps, adherence challenges, and the role of non-pharmacologic treatment may constrain conversion. Falsifiers of a bullish OMER read are continued absence of a credible development timeline, adverse or inconclusive trial evidence, or guidance showing no material advancement.

Key Decisions for Investors

• Do not initiate an OMER position on this market-research release alone; it supplies no OMS527-specific milestone or evidence sufficient to change company fundamentals.
• Place OMER on a catalyst watch: verify the candidate’s current trial phase, sponsor disclosures, study design, enrollment, and expected data timing before reassessing exposure.
• If OMER rallies materially on the report without a company-confirmed catalyst, consider fading the incremental move rather than underwriting the long-term market forecast; invalidate that view if Omeros announces a funded, time-bound clinical program with credible data.
• Revisit the opportunity only when clinical data establish efficacy and tolerability and there is evidence on treated-patient reach and payer access; these are the key missing inputs to commercial value.